Catalent Inc (CTLT) Releases Earnings Results, Misses Expectations By $-0.01 EPS

Catalent Inc (CTLT) reported quarterly earnings results on Monday, Aug-29-2016. The company reported $0.52 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $0.53. The company posted revenue of $532.20 million in the period, compared to analysts expectations of $500.46 million. The company’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.61 EPS.

Many Wall Street Analysts have commented on Catalent Inc. Catalent Inc was Upgraded by Wells Fargo to ” Outperform” on Jun 21, 2016. Catalent Inc was Upgraded by BofA/Merrill to ” Buy” on Jun 20, 2016.

Catalent Inc opened for trading at $24.8 and hit $25.81 on the upside on Tuesday, eventually ending the session at $25.53, with a gain of 3.36% or 0.83 points. The heightened volatility saw the trading volume jump to 12,65,010 shares. Company has a market cap of $3,183 M.

In a different news, on Jun 1, 2016, Matthew M Walsh (officer ) sold 21,197 shares at $28.85 per share price. According to the SEC, on Aug 19, 2015, John R Chiminski (director officer ) sold 38,505 shares at $33.87 per share price. On Apr 3, 2015, Scott Houlton (officer ) sold 16,253 shares at $30.61 per share price, according to the Form-4 filing with the securities and exchange commission.

Catalent Inc. is a provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products. The Company’s segments include Oral Technologies Medication Delivery Solutions and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies including formulation development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle. The Medication Delivery Solutions segment provides formulation development and manufacturing services for delivery of drugs and biologics administered through injection inhalation and ophthalmic routes using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing packaging storage and inventory management for drugs and biologics in clinical trials.

Catalent Inc

Leave a Reply

Catalent Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Catalent Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.